Respiratory disease Archives

News and Trends 16 Sep 2022

CHMP recommends approval of Beyfortus for prevention of RSV disease in infants

Beyfortus, which is being developed jointly by Sanofi and AstraZeneca, is a step closer to preventing respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Beyfortus (nirsevimab) for the prevention of RSV lower respiratory […]

September 16, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 5 Sep 2022

Synairgen to collaborate on study of patients hospitalized due to respiratory viruses

Synairgen plc is to collaborate on a University of Southampton study on acute respiratory viral infection and recovery in hospital patients. The UNIVERSAL (Understanding Infection, Viral Exacerbation and Respiratory Symptoms at Admission-Longitudinal) trial is an observational study being led by the Clinical Trials Unit of the University of Southampton in the U.K. to explore and […]

September 5, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 29 Jun 2022

Encouraging results from respiratory diseases vaccine trial

A biopharmaceutical company developing vaccines against infectious diseases has announced positive results for people with life threatening respiratory diseases. Icosavax says that in an interim phase 1/1b trial its vaccine IVX-121 has demonstrated robust immunological response to respiratory syncytial virus (RSV) in both young and older adult groups. The vaccine was generally tolerated with no […]

June 29, 2022 - 4 minutesmins - By Liza Laws

News and Trends 22 Mar 2022

Biotechs Carve out Niches in Cystic Fibrosis Treatment Space

Cystic fibrosis has proved resistant to treatments that provide long-lasting respite from the sticky mucus that affects the lungs and other organs. Emerging biotechs such as Kither Biotech as well as the old guard including Vertex are finding new ways to tackle the inherited disease. Cystic fibrosis is best known for causing thick mucus in […]

March 22, 2022 - 5 minutesmins - By Anita Chakraverty

ethris mrna therapy respiratory infection

News and Trends 1 Feb 2022

Ethris Raises €23M to Make Inhaled Respiratory Therapies from mRNA

Thanks to Covid-19 vaccines, messenger RNA (mRNA) technology has reached the mainstream. With a €23.4M Series B round, the German firm Ethris is riding the mRNA buzz by developing inhalable mRNA therapies for respiratory diseases. As Covid-19 mRNA vaccines entered the market for the first time in 2020, the wide potential of mRNA technology became […]

February 1, 2022 - 3 minutesmins - By Jonathan Smith

In Depth 22 Nov 2021

How Will We Be Treating Cystic Fibrosis 10 Years From Now?

Current treatments for cystic fibrosis are not suitable for all patients and have a limited effect on this life-threatening disease. But new advances in the field promise to overcome these hurdles. The cause of cystic fibrosis is very straightforward. Its treatment, however, is not. People diagnosed with cystic fibrosis have a mutation in a gene […]

November 22, 2021 - 9 minutesmins - By Clara Rodríguez Fernández

News and Trends 17 Aug 2021

Sanofi’s Translate Bio Buyout Shows Growing Hunger for mRNA Technology

Sanofi’s acquisition of its partner Translate Bio is a clear sign that pharmaceutical companies are interested in messenger RNA technologies beyond Covid-19. Based in Boston, US, Translate Bio develops mRNA therapies for a range of conditions, including respiratory, liver, and infectious diseases. The company’s €2.7B ($3.2B) buyout, announced by Sanofi earlier this month, seems a […]

August 17, 2021 - 5 minutesmins - By Mark Zipkin

small respiratory syncytial virus alzheimers disease sweden 1

News and Trends 28 May 2019

Viral Vaccines Could Be Weapons Against Alzheimer’s Disease

Scientists in Sweden have found that some viruses can increase the buildup of protein ‘plaques’ linked to Alzheimer’s disease, a discovery that could lead to new vaccines treating the condition. According to Kariem Ezzat, one of the lead researchers based in Stockholm University, the group is looking for industrial collaborators to develop vaccines against viruses […]

May 28, 2019 - 3 minutesmins - By Jonathan Smith

More News! 14 Jan 2019

Inhaled Lung Disease Treatment Encounters Mixed Results in Phase II Trial

An inhaled drug from British company Verona Pharma has failed to significantly improve lung function in patients with the lung disease chronic obstructive pulmonary disease, though it did produce some benefits. The 79 patients in the phase II trial suffered from chronic obstructive pulmonary disease, a condition where inflammation in the lungs restricts the airways […]

January 14, 2019 - 3 minutesmins - By Jonathan Smith

Morphogen IX pulmonary arterial hypertension

More News! 20 Dec 2018

Cambridge Company Raises €20M for Potential First in Lung Disease

Morphogen-IX, based in Cambridge, has raised €20.4M (£18.4M) to fund a new type of treatments for pulmonary arterial hypertension. The Series B financing will go towards the preclinical development of the company’s lead candidate, which has the potential to become the first to treat the condition rather than just addressing the symptoms. People with pulmonary […]

December 20, 2018 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 26 Nov 2018

Smart Asthma Inhaler Fails Phase III

It is bad news for asthma sufferers, as a UK biotech has abandoned the development of its smart inhaler after finding that it was no better than placebo in a Phase III trial. Over 52 weeks of treatment, the company Vectura tested whether the inhaler reduced the worsening of asthma symptoms, such as wheezing and […]

November 26, 2018 - 2 minutesmins - By Jonathan Smith

News and Trends 1 Aug 2018

London Biotech Raises €47M to Develop First Treatment Against RSV Virus

ReViral will dedicate the funds to run two clinical trials to test whether its antiviral can help patients at high risk from RSV infections. The respiratory syncytial virus (RSV) only causes mild cold symptoms in most people. But for small children and immunosuppressed patients, it can be deadly. “There are at present no approved therapies […]

August 1, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us